Although DNA-home testing is getting a lot more accessible for the everyday person, Senator Chuck Schumer claims doing so is more dangerous than we think.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
AstraZeneca has revealed plans to take part in a new drug development joint venture with a state-backed private equity fund.
UCSF is bringing primary care physicians and other providers together with geneticists, to incorporate genetic information in the care of patients.
If you have been keeping tabs on the website this week, then you’ll be aware at just how much of a booming year biotech companies are having.
The FDA has warned that it will be coming down hard on anyone carrying out do-it-yourself gene therapy, in a recent statement.
GlaxoSmith Kline (GSK) has welcomed the news that two of its drug regimen to treat HIV have won US approval, with its Juluca treatment.
Pfizer has found itself in a battle with several states who are intending to use some of its drugs to carry out executions.
One under the radar biotech could be trumping all its competitors, after it makes significant progress in potentially producing an Alzheimer’s treatment.
This Thanksgiving investors are thankful that the S&P 500 is up about 15% year to date, with that path expected to continue to the end of the year.
The three big players in the world of cloud computing released their quarterly earnings this week, and it’s clear who’s speeding ahead.
The FDA has released new guidelines in a bid to quicken the implementation of treatments involving human cells and tissues, including gene therapy.
It has been revealed that China now ranks third, trailing the likes of the US and the UK, in the list of most highly cited authors worldwide.
The first gene therapy for an inherited condition is approaching the US market, and companies are getting ready for the bidding war.